Newsroom

Recent News Releases

August 8, 2019 8/8/2019 Takeda Submits New Drug Application for a Subcutaneous Formulation of Vedolizumab for Patients with Moderately to Severely Active Ulcerative Colitis in Japan

July 31, 2019 7/31/2019 Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful Integration

July 31, 2019 7/31/2019 Takeda Reports Strong First Quarter FY2019 Results and Raises Guidance for the Full Year

July 26, 2019 7/26/2019 Termination of Co-promotion in Japan of Rheumatoid Arthritis Drug Enbrel^®

July 22, 2019 7/22/2019 Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease

SEE ALL NEWS AND RELEASES >

・For legacy Shire information, click here

Featured Topics

Discourse and progress in intestinal failure care

LEARN MORE

Takeda Moves to Transform Global Child Health Research with the London School of Hygiene & Tropical Medicine

LEARN MORE

Grand opening of Takeda’s new production facility, Grange Castle, Ireland

LEARN MORE

2019 Innovators in Science Award Winners Celebrated for Regenerative Medicine Research

LEARN MORE

Takeda breaks ground on a state of the art facility in Osaka, Japan

LEARN MORE

SEE ALL FEATURED TOPICS ARTICLES >

In the News

With this new original series featured in Asahi Shimbun Globe, President & CEO Christophe Weber gives his unique perspective on what he has learned from his upbringing in France and his international career.

LEARN MORE

Executive Leadership

Meet our Executive Leadership Team led by our President and CEO, Christophe Weber

LEARN MORE

For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.